Category Archives: Gene Therapy Clinics

Abuse in cell banking services a global problem – Bioprocess Insider – BioProcess Insider

The International Society for Cell and Gene Therapy (ISCT) has formed a consortium to tackle what it says is a rising number of unscrupulous and unproven cell banking players.

With the rise of interest in the cell and gene therapy sector, industry and the market have been plagued with unproven products and services from rogue actors looking to profit from ill-informed and sometimes desperate patients.

The US Food and Drug Administration (FDA) laid down a framework to tackle unapproved stem cell clinics, for example, and has issued warning letters,seized productsand instigated legal action to crack down on unscrupulous actors who often co-opt scientific terms and offer tokens of scientific legitimacy without backing from scientific studies and clinical evidence.

Image: iStock/Vitezslav Vylicil

Beyond stem cell clinics deceiving patients, with the approval of more cell and gene therapies, we see these profiteers moving to cell banking marketed to healthy people as well as patients, Laertis Ikonomou, co-chair off the International Society for Cell and Gene Therapy Presidential Task Force (PTF) on the Use of Unproven Cellular Therapies, told Bioprocess Insider.

There is potential for abuse in that the banking services may refer to direct-to-consumer unproven and unethical cell-based interventions will use cells from such cell banks. With global marketing and point of service kits, this is a borderless problem for all.

As such, the ISCT has formed a global consortium of professional and education societies to help combat the rise in the number of unproven commercial cell banking services. The consortium includes: The International Society for Stem Cell Research (ISSCR), Society for Immunotherapy of Cancer (SITC), American Society for Transplantation and Cellular Therapy (ASTCT), American Society of Gene & Cell Therapy (ASGCT), European Society for Blood and Marrow Transplantation (EBMT), Foundation for the Accreditation of Cellular Therapy (FACT), Joint Accreditation Committee ISCT-EBMT (JACIE) and the Forum for Innovative Regenerative Medicine (FIRM).

We do not currently have detailed statistics specifically on the number of cell banking services per region. It appears most are concentrated in the US, United Kingdom, and India, said Laertis Ikonomou.

Nevertheless, we consider such services to be part of a global market for unproven cellular therapies. This market has been estimated to be worth as much as $2.4 billion (2.13 billion). It is also estimated that currently approximately 60,000 patients every year globally are treated with unproven cellular therapies and charges for individual treatments can be as much as $40,000 (35,500) per treatment.

The initiative looks to protect legitimate cell-based product development and patients in various ways, Ikonomou said.

Any questionable offer of unproven cell-based products and services hurts the field of regenerative medicine. It erodes the publics trust and it gives the false impression that it is acceptable to offer products that have not been proven safe and effective.

Our collaborative effort aims to highlight these issues. We also want to demonstrate to patients the gap between the real clinical potential of such a service which is unclear at the moment and the overblown advertising claims of businesses offering commercial cell banking services.

While industry-led efforts such as this are necessary, he added increased regulatory enforcement such as the FDAs recent injunctions against unproven tissue-based clinics can rein in businesses that offer questionable cell-related services or products.

Exaggerated and misleading claims of future clinical use for banked cells may also fall under the purview of the US Federal Trade Commission. ISCT is in ongoing communication with regulatory and professional societies around the world, through the ISCT led Cell Therapy Liaison Meetings with FDA, Health Canada, and additional channels.

See more here:
Abuse in cell banking services a global problem - Bioprocess Insider - BioProcess Insider

Anti-Aging Products and Therapies Market Outlook: Investors Still Miss the Big Assessment – The Market Journal

Advance Market Analytics released a comprehensive study of 200+ pages on Anti-Aging Products and Therapies market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are Allergan plc (Ireland), Ipsen (France), Lanzhou Institute of Chemical Physics, Chinese Academy of Sciences (China), Estee Lauder Companies Inc. (United States), Avon Products, Inc. (United Kingdom), Galderma S.A. (Switzerland), LG Life Sciences, Ltd. (South Korea), Bohus Biotech AB (Sweden), Imeik Technology Development Co Ltd (China), Merck & Co., Inc. (United States), Gaoxin Zhangtong Co. Ltd. (China)

Request a sample report @ https://www.advancemarketanalytics.com/sample-report/36862-global-anti-aging-products-and-therapies-market

Due to rise in aging populations in several developed and developing countries, the anti-aging products and therapies market will grow robustly over the forecasted period. In addition to this, the rising number of medical tourism for cosmetic procedures, as well as technological advancement in the field of anti-aging will further escalate the demand for anti-aging treatments and ultimately anti-aging products. Moreover, the growing adoption of minimally invasive anti-aging treatments and introduction to non-invasive laser treatments will attract global population. However, some of the severe side effects for the skin treatments might stagnate the demand for anti-aging products and treatments. Aging relates to maturing or growing old in terms of endurance, agility, strength, basal metabolism, speed of reaction, hearing acuity and many others. In case of geriatric population, the skin drier & less elastic; bones are comparatively brittle, and the teeth are shed.

Market Segmentationby Type (Human Growth Hormone, Stem Cell, Placenta, Botulinum Toxin, Hyaluronic Acid), Application (Anti-Pigmentation Therapy, Anti-Cellulite Treatment, Anti-Wrinkle Treatment, Acne Management, Scar Treatment, Others), Active Ingredients (Retinol, Peptides, Argirelline), Distribution Channel (Dermatology Clinics, Hospitals, Pharmacies, Drug Stores, Rejuvenation Centers, Others.), Service (BOTOX, Proteomics, Gene Therapy, HRT, Dermal Fillers, Plastic Surgery)

Make an enquiry before buying this Report @ https://www.advancemarketanalytics.com/enquiry-before-buy/36862-global-anti-aging-products-and-therapies-market

Whats Trending in Market: Introduction to Highly Advanced Skin Treatments such as Neuromodulators For Tauter Skin

Adoption of New Age Fillers like Hyaluronic acid and Calcium Hydroxyapatite Fillers

Growth Drivers: Increasing Geriatric Population across the Globe will boost the Demand

Rising Health Consciousness Among Consumers

Restraints: Significant Side-Effects of the Dermal Treatments for instance; Chemicals Available in Cosmetic Products are Found in Biopsies from Breast Tumors

Excessive Use might Disturb the Hormone Function of Consumer

View Detailed Table of Content @ https://www.advancemarketanalytics.com/reports/36862-global-anti-aging-products-and-therapies-market

Country level Break-up includes:North America (United States, Canada and Mexico)Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

On Special Request we do offer a dedicated and focus report on regional or by country level scope.

GET FULL COPY OF United States Anti-Aging Products and Therapies market study @ USD 2000

And, Asia-Pacific Anti-Aging Products and Therapies market study @ USD 2500

Major Highlights of TOC:

Chapter One: Market Overview

Scope/Objective of the Study

Chapter Two: Executive Summary - Free of Cost

Chapter Three: Market Dynamics USD400

Market Drivers, Market Challenges, Market Trends

Chapter Four: Market Factor Analysis USD400

Supply/Value Chain Analysis, Porters Five Forces, PESTEL analysis, Market Entropy, Patent & Trademark Analysis, Market Development Scenario

Chapter Five and Seven: Global Anti-Aging Products and Therapies, by Market Segmentation and Region (value, volume**) (2013-2024) USD2400

Global Anti-Aging Products and Therapies

By Type (Human Growth Hormone, Stem Cell, Placenta, Botulinum Toxin, Hyaluronic Acid)

By Application (Anti-Pigmentation Therapy, Anti-Cellulite Treatment, Anti-Wrinkle Treatment, Acne Management, Scar Treatment, Others)

By Active Ingredients (Retinol, Peptides, Argirelline)

By Distribution Channel (Dermatology Clinics, Hospitals, Pharmacies, Drug Stores, Rejuvenation Centers, Others.)

By Service (BOTOX, Proteomics, Gene Therapy, HRT, Dermal Fillers, Plastic Surgery)

Global Anti-Aging Products and Therapies Region

North America (United States, Canada and Mexico)

Europe (Germany, France, United Kingdom, Spain, Italy, Netherlands, Switzerland, Nordic, Others)

Asia-Pacific (Japan, China, Australia, India, Taiwan, South Korea, Middle East & Africa, Others)

Chapter Six: Global Anti-Aging Products and Therapies Manufacturers/Players Analysis USD1200

Competitive Landscape (Direct & Indirect Competitors), Market Share Analysis, Peer Group Analysis (2018), BCG Matrix, Company Profile, Downstream Buyers & Upstream Suppliers

..

Chapter Nine: Methodology/Research Approach, Data Source, Disclaimer

** If applicable* Customized Section/Chapter wise Reports or Regional or Country wise Chapters are also available.

Buy this report @ https://www.advancemarketanalytics.com/buy-now?format=1&report=36862

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact Us:CRAIG FRANCIS (PR & Marketing Manager)sales@advancemarketanalytics.comPh: +1 (206) 317 1218

View original post here:
Anti-Aging Products and Therapies Market Outlook: Investors Still Miss the Big Assessment - The Market Journal

Tip Sheet: A clever way to make an AIDS vaccine; how a common cancer mutation actually drives cancer; and a new process that regulates red blood cell…

MEDIA CONTACT

Available for logged-in reporters only

Cancer and infectious disease

Newswise New trial aims to curb HPV-related cancers in HIV+ women and children Fred Hutch researchers just received funding from the National Institutes of Health for a five-year collaboration designed to help a population at high risk for cervical and other HPV-related cancers: women and children living with HIV. Through the project, which comes with around $1.8 million each year, researchers will conduct three separate trials in three major Latin American cities: Lima, Peru; Rio de Janeiro, Brazil; and Santa Domingo, Dominican Republic. Many cancers have been linked to the human papillomavirus, or HPV, including cervical, anal, penile, vulvar and some head and neck cancers. While cervical cancer rates in the U.S. have stayed low for years thanks to screening and an effective HPV vaccine, it remains the fourth-leading cause of cancer and cancer death worldwide.Media contact: Claire Hudson, crhudson@fredhutch.org, 206.667.7665

_____________________________________________________________________________________________________________________HIV/AIDS research

Baiting for B cells: A clever new way to make an AIDS vaccine Researchers at Fred Hutch have developed a new strategy to counter the frustrating ability of HIV to sidestep vaccines designed to block it. In a pair of papers recently published in the Journal of Experimental Medicine, Hutch vaccine researchers explain how they were able to use a tiny chunk of protein as bait to fish for extremely rare white blood cells hidden within ordinary blood. When these rare B cells bind with the bait, they multiply and are not so rare anymore. Thats important, because these B cells are just a few evolutionary steps away from generating with some nudging from a series of additional injections the kind of long-lasting immune responses needed for an effective HIV vaccine. Media contact: Claire Hudson, crhudson@fredhutch.org, 206.667.7665

_____________________________________________________________________________________________________________________Healthcare Economics

Fred Hutch issues report on cancer care in Washington state The Community Cancer Care in Washington State: Quality and Cost Report 2019 measured performance in four areas among 29 clinics by linking health utilization data with cost data from public and private insurers in the state. The report found room for improvement in reducing emergency department visits and hospitalizations during chemotherapy and in providing appropriate end-of-life care. The report is part of a six-year collaboration among patient partners, hospitals and clinics delivering cancer care, health insurance plan administrators, researchers, health quality organizations, policymakers and government leaders led by the Hutchinson Institute for Cancer Outcomes Research, a research group at Fred Hutch whose mission is to improve cancer care in ways that will reduce the economic and human burden of cancer. Media contact: Claire Hudson, crhudson@fredhutch.org, 206.667.7665

_____________________________________________________________________________________________________________________Public Health Sciences

How a common cancer mutation actually drives cancer and how to correct it A new, multicenter study led by researchers at Fred Hutch and Memorial Sloan Kettering Cancer Center determined how a single mutation in splicing factor 3b subunit 1(SF3B1), the most frequently mutated splicing factor gene, drives the formation of many cancers. The findings were published earlier this month in the journal Nature. Dr. Robert Bradley, associate member of Fred Hutchs Public Health Sciences and Basic Sciences divisions, andDr. Omar Abdel-Wahab, associate member of Memorial Sloan Ketterings Human Oncology and Pathogenesis Program, led the study to discover howSF3B1gene mutations cause cancer.Media contact: Tom Kim, tomkim@fredhutch.org, 206.667.6240 _____________________________________________________________________________________________________________________Human Biology

Scientists discover new process shaping red blood cell development Fred Hutch scientists have discovered a process that regulates the earliest stages of red blood cell development. The findings, published recently in the journal Nature Communications, could shed light on what goes wrong in certain blood cancers and anemias. The team showed for the first time that developing red blood cells use a particular molecular process to ensure that red blood cell-specific proteins are made. Blocking the molecular machinery prevented the normal development of blood cells. Media contact: Molly McElroy, mwmcelro@fredhutch.org, 206.667.6651

Age-old arms race points way to new-and-improved antiviral proteinFred Hutch scientists have recently shown that they could use insights from the ancient tug-of-war between viruses and their hosts to evolve a better antiviral protein in the lab. The work was published last month in the journal PLOS Biology.The findings address fundamental questions about evolution, including whether antiviral genes that adapt against certain viruses become less equipped to deal with new viral challenges. Media contact: Molly McElroy, mwmcelro@fredhutch.org, 206.667.6651

_____________________________________________________________________________________________________________________October Recognitions

Researchers at Fred Hutch are often recognized for their work. Were proud to celebrate their achievements and grateful to the awarding organizations.

Infectious Diseases Society to honor Dr. Michael Boeckh

Fred Hutchled team receives $6M to study deadly brain tumor

New study aims to transform myeloma therapy into cure

Dr. M. Elizabeth Betz Halloran elected to National Academy of Medicine

# # #

AtFred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutchs pioneering work inbone marrow transplantationled to the development ofimmunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nations first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Womens Health Initiative and the international headquarters of theHIV Vaccine Trials Network.

Original post:
Tip Sheet: A clever way to make an AIDS vaccine; how a common cancer mutation actually drives cancer; and a new process that regulates red blood cell...

Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) – The Market Expedition

obal Cell Therapy Technologies Marketwas valued US$ 12 billion in 2018 and is expected to reach US$ 35 billion by 2026, at CAGR of 12.14 %during forecast period.

The objective of the report is to present comprehensive assessment projections with a suitable set of assumptions and methodology. The report helps in understanding Global Cell Therapy Technologies Market dynamics, structure by identifying and analyzing the market segments and projecting the global market size. Further, the report also focuses on the competitive analysis of key players by product, price, financial position, growth strategies, and regional presence. To understand the market dynamics and by region, the report has covered the PEST analysis by region and key economies across the globe, which are supposed to have an impact on market in forecast period. PORTERs analysis, and SVOR analysis of the market as well as detailed SWOT analysis of key players has been done to analyze their strategies. The report will to address all questions of shareholders to prioritize the efforts and investment in the near future to the emerging segment in the Global Cell Therapy Technologies Market.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/31531

Global Cell Therapy Technologies Market: OverviewCell therapy is a transplantation of live human cells to replace or repair damaged tissue and/or cells. With the help of new technologies, limitless imagination, and innovative products, many different types of cells may be used as part of a therapy or treatment for different types of diseases and conditions. Celltherapy technologies plays key role in the practice of medicine such as old fashioned bone marrow transplants is replaced by Hematopoietic stem cell transplantation, capacity of cells in drug discovery. Cell therapy overlap with different therapies like, gene therapy, tissue engineering, cancer vaccines, regenerative medicine, and drug delivery. Establishment of cell banking facilities and production, storage, and characterization of cells are increasing volumetric capabilities of the cell therapy market globally. Initiation of constructive guidelines for cell therapy manufacturing and proven effectiveness of products, these are primary growth stimulants of the market.

Global Cell Therapy Technologies Market: Drivers and RestraintsThe growth of cell therapy technologies market is highly driven by, increasing demand for clinical trials on oncology-oriented cell-based therapy, demand for advanced cell therapy instruments is increasing, owing to its affordability and sustainability, government and private organization , investing more funds in cell-based research therapy for life-style diseases such as diabetes, decrease in prices of stem cell therapies are leading to increased tendency of buyers towards cell therapy, existing companies are collaborating with research institute in order to best fit into regulatory model for cell therapies.Moreover, Healthcare practitioners uses stem cells obtained from bone marrow or blood for treatment of patients with cancer, blood disorders, and immune-related disorders and Development in cell banking facilities and resultant expansion of production, storage, and characterization of cells, these factors will drive the market of cell therapy technologies during forecast period.

On the other hand, the high cost of cell-based research and some ethical issue & legally controversial, are expected to hamper market growth of Cell Therapy Technologies during the forecast period

AJune 2016, there were around 351 companies across the U.S. that were engaged in advertising unauthorized stem cell treatments at their clinics. Such clinics boosted the revenue in this market.in August 2017, the U.S. FDA announced increased enforcement of regulations and oversight of clinics involved in practicing unapproved stem cell therapies. This might hamper the revenue generation during the forecast period; nevertheless, it will allow safe and effective use of stem cell therapies.

Global Cell Therapy Technologies Market: Segmentation AnalysisOn the basis of product, the consumables segment had largest market share in 2018 and is expected to drive the cell therapy instruments market during forecast period at XX % CAGR owing to the huge demand for consumables in cell-based experiments and cancer research and increasing number of new product launches and consumables are essential for every step of cell processing. This is further expected to drive their adoption in the market. These factors will boost the market of Cell Therapy Technologies Market in upcoming years.

On the basis of process, the cell processing had largest market share in 2018 and is expected to grow at the highest CAGR during the forecast period owing to in cell processing stage,a use of cell therapy instruments and media at highest rate, mainly in culture media processing. This is a major factor will drive the market share during forecast period.

Global Cell Therapy Technologies Market: Regional AnalysisNorth America to held largest market share of the cell therapy technologies in 2018 and expected to grow at highest CAGR during forecast period owing to increasing R&D programs in the pharmaceutical and biotechnology industries. North America followed by Europe, Asia Pacific and Rest of the world (Row).

Do Inquiry Before Purchasing Report Here:https://www.maximizemarketresearch.com/inquiry-before-buying/31531

Scope of Global Cell Therapy Technologies Market

Global Cell Therapy Technologies Market, by Product

Consumables Equipment Systems & SoftwareGlobal Cell Therapy Technologies Market, by Cell Type

Human Cells Animal CellsGlobal Cell Therapy Technologies Market, by Process Stages

Cell Processing Cell Preservation, Distribution, and Handling Process Monitoring and Quality ControlGlobal Cell Therapy Technologies Market, by End Users

Life Science Research Companies Research InstitutesGlobal Cell Therapy Technologies Market, by Region

North America Europe Asia Pacific Middle East & Africa South AmericaKey players operating in the Global Cell Therapy Technologies Market

Beckman Coulter, Inc. Becton Dickinson and Company GE Healthcare Lonza Merck KGaA MiltenyiBiotec STEMCELL Technologies, Inc. Terumo BCT, Inc. Thermo Fisher Scientific, Inc. Sartorius AG

MAJOR TOC OF THE REPORT

Chapter One: Cell Therapy Technologies Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three: Global Cell Therapy Technologies Market Competition, by Players

Chapter Four: Global Cell Therapy Technologies Market Size by Regions

Chapter Five: North America Cell Therapy Technologies Revenue by Countries

Chapter Six: Europe Cell Therapy Technologies Revenue by Countries

Chapter Seven: Asia-Pacific Cell Therapy Technologies Revenue by Countries

Chapter Eight: South America Cell Therapy Technologies Revenue by Countries

Chapter Nine: Middle East and Africa Revenue Cell Therapy Technologies by Countries

Chapter Ten: Global Cell Therapy Technologies Market Segment by Type

Chapter Eleven: Global Cell Therapy Technologies Market Segment by Application

Chapter Twelve: Global Cell Therapy Technologies Market Size Forecast (2019-2026)

Browse Full Report with Facts and Figures of Cell Therapy Technologies Market Report at:https://www.maximizemarketresearch.com/market-report/global-cell-therapy-technologies-market/31531/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Lumawant Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: sales@maximizemarketresearch.com

Contact: +919607065656/ +919607195908

Website: http://www.maximizemarketresearch.com

Original post:
Global Cell Therapy Technologies Market Industry Analysis And Forecast (2018-2026) - The Market Expedition

Davenport & Company Upped By $3.56 Million Its Sgmo (SGMO) Holding; EMPOWER CLINICS ORDINARY SHARES (EPWCF) Shorts Raised By 2360% – MS Wkly

Davenport & Company Llc increased Sgmo (SGMO) stake by 516.32% reported in 2019Q2 SEC filing. Davenport & Company Llc acquired 355,876 shares as Sgmo (SGMO)s stock rose 5.54%. The Davenport & Company Llc holds 424,801 shares with $4.58M value, up from 68,925 last quarter. Sgmo now has $1.05 billion valuation. The stock increased 3.16% or $0.29 during the last trading session, reaching $9.46. About 761,245 shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has declined 8.32% since November 6, 2018 and is downtrending. It has underperformed by 8.32% the S&P500. Some Historical SGMO News: 16/05/2018 Bioverativ And Sangamo Announce FDA Acceptance Of IND Application For Gene-Edited Cell Therapy BIVV003 To Treat Sickle Cell Disease; 23/05/2018 Biotech Analysis Central Preview Series: Sangamo Therapeutics; 25/04/2018 SANGAMO THERAPEUTICS OFFERING PRICES AT $16.25/SHR; 17/04/2018 SANGAMO THERAPEUTICS SAYS EXECS EMAIL WAS COMPROMISED; 17/04/2018 SANGAMO THERAPEUTICS: CONFIDENTIAL, SENSITIVE INFO ACCESSED; 17/04/2018 SANGAMO THERAPEUTICS-PROPRIETARY, CONFIDENTIAL, OTHER SENSITIVE INFORMATION OF CO, OTHER ENTITIES ACCESSED, MAY HAVE BEEN COMPROMISED DUE TO INCIDENT; 17/04/2018 SANGAMO THERAPEUTICS INC DATA SECURITY INCIDENT WAS LIMITED TO COMPROMISE OF SENIOR EXECUTIVES COMPANY EMAIL ACCOUNT FOR APPROXIMATELY 11 WEEKS; 23/04/2018 DJ Sangamo Therapeutics Inc, Inst Holders, 1Q 2018 (SGMO); 03/05/2018 Sangamo Therapeutics: Michael Holmes Promoted to Chief Technology Officer; 01/05/2018 Sangamo Therapeutics Announces Presentations At 2018 Annual Meeting Of The American Society Of Gene & Cell Therapy

EMPOWER CLINICS INC ORDINARY SHARES (OTCMKTS:EPWCF) had an increase of 2360% in short interest. EPWCFs SI was 12,300 shares in November as released by FINRA. Its up 2360% from 500 shares previously. With 22,200 avg volume, 1 days are for EMPOWER CLINICS INC ORDINARY SHARES (OTCMKTS:EPWCF)s short sellers to cover EPWCFs short positions. It closed at $0.029 lastly. It is down 0.00% since November 6, 2018 and is . It has by 0.00% the S&P500.

More notable recent Sangamo Therapeutics, Inc. (NASDAQ:SGMO) news were published by: Finance.Yahoo.com which released: Is Sangamo Therapeutics, Inc. (SGMO) Going to Burn These Hedge Funds? Yahoo Finance on October 28, 2019, also Fool.com with their article: Should Investors Buy or Sell Sangamo Therapeutics Right Now? Motley Fool published on October 08, 2019, Businesswire.com published: Sangamo Therapeutics Appoints Sung Lee as Executive Vice President and Chief Financial Officer Business Wire on November 01, 2019. More interesting news about Sangamo Therapeutics, Inc. (NASDAQ:SGMO) were released by: Finance.Yahoo.com and their article: What Kind Of Shareholder Owns Most Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Stock? Yahoo Finance published on October 01, 2019 as well as Finance.Yahoo.coms news article titled: If You Had Bought Sangamo Therapeutics (NASDAQ:SGMO) Stock Three Years Ago, You Could Pocket A 93% Gain Today Yahoo Finance with publication date: May 05, 2019.

Investors sentiment increased to 1.57 in Q2 2019. Its up 0.29, from 1.28 in 2019Q1. It is positive, as 24 investors sold SGMO shares while 32 reduced holdings. 26 funds opened positions while 62 raised stakes. 73.13 million shares or 14.12% more from 64.08 million shares in 2019Q1 were reported. Advisory Svcs Ntwk Ltd accumulated 6,267 shares or 0% of the stock. Prelude Management Ltd Liability Corp has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Cranbrook Wealth Mgmt Llc stated it has 1,620 shares or 0% of all its holdings. Baker Bros Lp stated it has 999,823 shares. Geode Mgmt Limited Liability reported 1.49 million shares stake. California State Teachers Retirement Systems has 176,863 shares for 0% of their portfolio. Rafferty Asset Limited Liability Com reported 262,377 shares. Vigilant Cap Mngmt Limited invested in 5,000 shares or 0.01% of the stock. Principal Financial holds 0% or 28,192 shares. Baldwin Brothers Incorporated Ma reported 1,500 shares. Cubist Systematic Strategies Ltd Liability Co reported 68,478 shares. Nuveen Asset Mgmt Lc, a Illinois-based fund reported 790,682 shares. Goldman Sachs Grp Inc Inc invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Tiverton Asset Mngmt Ltd Company holds 0% or 7,316 shares. Legal & General Gp Public Limited Com accumulated 23,425 shares or 0% of the stock.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Read the original:
Davenport & Company Upped By $3.56 Million Its Sgmo (SGMO) Holding; EMPOWER CLINICS ORDINARY SHARES (EPWCF) Shorts Raised By 2360% - MS Wkly

Dr Batra’s have launched a new genetics-based therapy that predicts future diseases – Gulf Today

Dr Mukesh Batra, the owner of Dr Batras clinics.

Mitchelle DSouza, Sub-editor/Reporter

The founder and chairman of Dr Batras group of companies, Dr Mukesh Batras name has become a byword for homeopathy.

The pioneering Indian doctor-cum-entrepreneur has built a legacy which includes a network of clinics, day-care aesthetic centres, and health and wellness products.

We caught up with Dr Batra at his Healthcare City clinic in Dubai, where he spoke at length about the workings of homeopathy and introduced us to the new Geno-Homeopathy treatment launched by the brand.

Can you explain what homeopathy treatment is for those who dont have a clear understanding? How does it work in comparison to conventional medicine?

Theres actually a misconception that its not well known. For emergencies and conventional problems, allopathy is the go-to. Like a heart attack, surgeries, gunshot wounds and so on.

However, homeopathy is safe for anything that is chronic and long lasting such as psychosomatic problems like stress, anxiety, and depression related issues; allergies, skin and hair problems.

We treat a wide range of illnesses such as asthma, arthritis, anxiety, depression, backache, cervical spondylitis, kidney stones in primary stage, warts, piles, PCOD, nasal polyps etc.

It has no side-effects and is completely painless and non-invasive. It goes to the root of the problem, nipping it in the bud, rather than just supressing it temporarily with pain killers.

"People are getting disillusioned with chemical medication, its side effects and opting for substances that are natural and safe, and holistic remedies, which homeopathy includes.

Is it true that homeopathy is slower in addressing an ailment in comparison to allopathy?

Its partly true, but not entirely. If you come to allopathy for a chronic sinus problem, you pop a pill and supress it. Similarly for a skin allergy, an ointment will supress the symptoms. The moment you stop, it flares up again.

So when you look at suppression, it is quick in allopathy, but thats not a cure. In conventional medicine, treatment is as slow as homeopathy or maybe even slower

For instance, a patient may be supressing his/her migraine or skin problem for the last 10 years with allopathy by taking pain killers and anti-inflammatories but without a proper solution.

However, if he/she were to take homeopathy for just 10 months, it would cure it, and hence that makes it much faster and effective as it gets to the root of the cause.

The reason it may feel seemingly long is because most illnesses are chronic, long-standing and deep-rooted.

Geno-Homeopathy treatment employs a gene test to predict, pre-empt and treat an illness. Charles Bertram/TNS

Can you give us an insight into the new Geno-Homeopathy treatment launched in the UAE?

As you may be aware, genetic DNA studies have been around for some years and have become more popular off late, thanks to Angelina Jolie creating awareness by positively testing herself for a cancer gene.

This helps predict and pre-empt an illness. How this works is that you have genes that are inherited, with 99.9 per cent of them being normal. But 0.1 per cent genes can be faulty and that percentage decides what diseases we carry.

A gene is like a finger print, it never changes. So just like you would use your finger print or pupil for identity, this is used for gene mapping through a simple sputum test. Now that 0.1 percentage gene decides how healthy I can be and which diseases I am likely to suffer from.

So with Geno-Homeopathy we can now analyse those 0.1 per cent genes. We completed one year in India in September and did 15,000 cases of genetic mapping.

This technique gives you your disease propensity and can tell you, for example, whether youll go bald five or 10 years from now; if youre prone to heart attack or diabetes it will tell you when youre likely to get it.

Post an analysis, a homeopathic treatment is offered to the patient to treat a condition. So this can be almost life-saving and is now within peoples reach in the UAE.

Angelina Jolie found out through genetic testing similar to Geno-Homeopathy that she is at a high risk of developing breast cancer.Marechal Aurore/TNS

There are a lot of cynics out there who question the scientific basis of homeopathy. What do you have to say to that?

A research we conducted three to four years ago found that a majority of people in Indian metros were taking homeopathy as the first choice of treatment. Pharma is growing at 10 per cent while homeopathy is growing at 30 per cent all over the world.

People are getting disillusioned with chemical medication, its side effects and opting for substances that are natural and safe, and holistic remedies, which homeopathy includes.

To give you a little perspective, there are around 300 people dying of drug reaction in America alone everyday which is equal to a Boeing crash. But it doesnt get as much attention, which can be pinned on the strong medical lobby.

So theres a gradual shift happening from allopathy to homeopathy not just in India but all over the world.

That being said, there are a lot of cynics and the lobbies that plant various stories. In spite of all this homeopathy is growing exponentially. The proof of the pudding is in eating it, so people should give it a try before denouncing it.

See the article here:
Dr Batra's have launched a new genetics-based therapy that predicts future diseases - Gulf Today

Deepak Chopra Has Never Been Sick – The New Yorker

Deepak Chopra, the doctor and self-help guru, who turns seventy-three next week, has written more than one book for every year he has been alive. Chopra was born in New Delhi and studied medicine in India before moving to the United States, in 1970. After practicing as an endocrinologist in Massachusetts, he became involved in the Transcendental Meditation movement. He eventually relocated to the West Coast, left T.M. behind, and became a spiritual adviser to Michael Jackson and other celebrities. A quarter century later, his books have sold millions of copies, and his television appearancesespecially alongside Oprah Winfreyhave made him perhaps the most prominent advocate for alternative medicine recognizable around the world.

Chopras work evinces a consistent skepticism toward the scientific consensushe has called into question whether evolution is merely a process of the mindand a firm belief that mental health can determine physical reality. He has written of a place called perfect healththe title of one of his books, and now the slogan for one of his wellness retreatsin which human beings can go somewhere internally that is free from disease, that never feels pain, that cannot age or die. These beliefs have made him controversial among doctors and scientists. In 1998, Chopra was awarded the satirical Ig Nobel Prize for his unique interpretation of quantum physics as it applies to life, liberty, and the pursuit of economic happiness. A random Chopra-quote generator is popular online, and Chopra has been called out for tweeting and writing phrases that, in the words of one paper, may have been constructed to impress upon the reader some sense of profundity at the expense of a clear exposition of meaning or truth. (Example: Attention and intention are the mechanics of manifestation.)

Chopras latest book is Metahuman: Unleashing Your Infinite Potential, and it touches on a number of themes that have been present throughout his career: that human beings can become metahuman by reaching a new place of awareness; that science has served to block the way to the absolute freedom that metahuman holds out; and that self-improvement can move creation itself. I recently spoke by phone with Chopra. During our conversation, which has been edited for length and clarity, we discussed controversial remarks he has made about cancer and AIDS, his claim to have never been even a tiny bit sick, and whether there is a reality that exists independently of our own minds.

How do you define yourself and what you do?

I would say that to define oneself is to limit oneself. But Ive had various roles through my life. Im an internist, an endocrinologist, a neuro-endocrinologist; a teacher of integrative medicine and an author; a husband, a son, a father, a child.

I know you are a doctor, but does thinking about yourself as a doctor seem limiting to you in some way?

It seems limiting to me, but I would say I think of myself closer to a healer. Because, when I look at healing and the origins of the word healing, its related to the word whole. So wholeness means everything, including body, mind, and spirit, and the environment. I think of myself as a doctor who is interested in the physical body, but also in all aspects of human experiencehuman emotions, human thinking, human experience, and, ultimately, in understanding ourselves beyond the conditioned mind. So I would say I want to be a healer. Thats my aspiration.

At what point in your career did you become famous?

Some people think it happened with The Oprah Winfrey Show, in 1993, when she did a one-to-one with me for a book called Ageless Body, Timeless Mind, which then stayed on the New York Times best-seller list for thirty-some weeks. Actually, my most well-known book is The Seven Spiritual Laws of Success. But I have to say that Oprah helped me a lot with the launch of my career, and shes been an ally ever since. Weve taught six million people meditation online together.

How many books have you written now?

This is my ninetieth book.

Would you say your writing process has changed between your first and your ninetieth?

Yes. My process was more structured in the past. And now I feel its more a flow than anything else. I used to always be told by media and publishers, and even the BBC when I was in England, to dumb everything down, and I used to, and I dont anymore. I feel free to say whatever I want to.

Ive been looking for a through line in your work, and the one that Ive noticed most is the idea that our minds can determine reality, or that theres a connection between our minds and reality. Is that a fair way of phrasing it?

Yes. The correct phrase would be that our experience of the world, and of our body, is a projection of our conditioned mind. So, when youre born, you have no human constructs. Youre looking at the world as a messy, gooey experience of color, form, shapes, sounds, pictures, smells, tastes, and random thoughts, which are yet not clear. But then a construction process begins. And so youre told, Youre male, youre of a religious background, ethnic background, nationality, gender. And that begins to create a provisional identity. And then that provisional identity has perceptual experiences but interprets them as the physical body and the world. But, in the deeper reality, theres no such thing. All there is is consciousness experiencing itself perceptually, as perceptual activity, which is species-specific. You dont see the same world as a painted lady, a species of butterfly that smells the world with an antenna, tastes the world with her feet. So what is the picture of the world to a snake that navigates through the experience of infrared?

If you and a snake perceive the world differently and experience it differently, does that mean that the world is actually different? Or does it just mean that we perceive it differently?

We can only experience a narrow band with our perceptual reality. So there is no such thing as a physical world. Thats where Im going. Our experience of the world is species- and culture-specific. And that is what we interpret as fundamental reality.

You once said, Consciousness is key to evolution and we will soon prove that. What did you mean?

You know, Ive said in the past that Darwinian evolution is a human constructthat, ultimately, consciousness drives at least human evolution. We can direct our evolution by the choices we make. And now that we know the science of epigenetics and neuroplasticity, we can see very clearly that, because we are self-aware, unlike other species, we can consciously direct our evolution. And that is what epigenetics and neuroplasticity are showing us.

Epigenetics is not that we can direct our evolution, though, is it?

Well, we can trigger the activity of certain genes and decrease the activity of certain other genes. So, when people practice self-reflection or mindful awareness, or they have the experience of transcendence, you can actually see which genes get activated and which genes get deactivated. Theres a mechanism to that. So you can actually activate the genes that cause self-regulation or homeostasis, and actually decrease the activity of the genes that cause inflammation. So what is healing? It is nothing but self-regulation or homeostasis. And what is disease is mostly linked to chronic inflammation. Only five per cent of disease-related gene mutations are fully penetrant, which means they guarantee the disease. That includes everything, from Alzheimers to cancer to autoimmune disease. Only five per cent is related to genetic determinism. The rest is influenced by life style. [Gerard Karsenty, the chair of the Department of Genetics and Development at Columbia University Irving Medical Center, says, Those assumptions include non-Mendelian diseases. It is for now hard to precisely assess in multigenic diseases the extent of the contribution of gene mutations and the one of lifestyle taken in a broad sense. This is particularly true for autoimmune diseases that hit at all ages, including during childhood and with a higher incidence in women.]

You tweeted, An emerging view, alternate to Darwins random mutations & natural selection is that consciousness may be the driver of complexity/evolution.

Correct. But there are a few people who agree with that.

So, you know, scientists generally are nave realists. Which means they look at the picture of the world, and thats what it is.

What do you do, if not that?

Ive become aware of that which is having the experience rather than the experience, which in spiritual traditions is called the self. The body, the mind, and the world are the self.

It seems like all of these things are fitting under the rubric of what we were talking about earlier about consciousness and reality. I know you once said something like, The moon doesnt exist unless someone sees it. Is that right?

No, no. That was Einsteins quote, by the way. He actually said, I refuse to believe that the moon doesnt exist if no one is looking at it. [In his biography of Einstein, Abraham Pais recounted an interaction he had with the physicist who asked me if I really believed that the moon exists only if I look at it.] Thats a statement coming from a nave realist. The moon that you and I see is a human experience. A horseshoe crab doesnt have that experience living in the depths of the ocean.

Einstein was incredulously asking someone whether they really believe that the moon only exists when its looked at. Correct?

Yes. The moon is an experience in human consciousness. The moon that you and I see is an experience in human consciousness. If there was no human consciousness, no body, mind to go with it, there would be no awareness of the moon.

But the moon would still be there, correct?

How do you prove that? How do you validate that? How do you disprove that? How do you prove an unobserved phenomenon?

The moon is a human story. The universe is a human story. Its a human construct, or human experiences, and interpreted by the human mind.

So this would be akin to the question, which Im sure weve all heard, that if a tree falls in the forest and no one hears it, does it make a sound?

Correct. The sound is only in consciousness. Before that its a vibration of air molecules.

But the vibration of air molecules are occurring. Correct?

The vibration of air molecules is a human construct for a human mode of knowing and experience in human consciousness, so yes, they are constructs. The air molecules are as much of a construct as latitude and longitude, as The New Yorker, as Greenwich Mean Time, as money, as Wall Street, as Manhattan.

Im not sure what that means.

Human constructs are human ideas around modes of human knowing.

I see.

So an atom, a molecule, a force field, vibration of moleculesthese are all human constructs.

So its not that the tree is making a sound and we just happen to be there or not there to hear it. Its that the sound is only present to the degree that we are also present.

Actually, there is no tree and there is no sound and there is no body and there is no mind. Theres only consciousness thats having an experience. The rest is human constructs.

In your book Quantum Healing, you wrote, Research on spontaneous cures of cancer conducted in both the United States and Japan has shown that just before the cure appears, almost every patient experiences a dramatic shift in awareness. He knows that he will be healed and he feels that the force responsible is inside himself, but not limited to him. It extends beyond his personal boundaries throughout all of nature. Suddenly he feels, I am not limited to my body. All that exists around me is part of myself. At that moment, such patients apparently jumped to a new level of consciousness that prohibits the existence of cancer. Then the cancer cells either disappear, literally overnight in some cases, or at the very least stabilize without damaging the body any further.

So if you were a scientist and you saw one case of that, one in a billion, youd want to know the mechanism. And I feel the mechanism is a return to fundamental homeostasis, which means self-regulation, and total absence of fear, including the fear of death. Because your identity is no longer your body-mind.

And so is that more important than medicine?

No, I think medicine is very useful for acute illness. If you have pneumonia, I certainly tell you to take an antibiotic. You break your leg, Id have you see an orthopedic surgeon. If you have cancer, there are many types of chemotherapy and radiation and stem-cell therapies and immunotherapies that will help you. But, in todays age, if you dont understand that integrating that with good sleep, with meditation, with stress management, with mindfulness, with healthy emotions, with good food that actually changes the activity of your microbiomeif you dont conform to that, then youre out of date.

This is from your book Perfect Health: There exists in every person a place that is free from disease, that never feels pain, that cannot age or die. When you go to this place, limitations which all of us accept cease to exist. They are not even entertained as a possibility. This is the place called perfect health. Visits to this place may be very brief, or they may last for many years. Even the briefest visit, however, instills a profound change. As long as you are there, the assumptions that hold true for ordinary existence are altered. If you can be in this place, why would you necessarily need medicine to stay healthy?

We dont. Ive never used medicine myself. Im seventy-three years old, never been in the hospital, never had surgery. Cant even remember having a cold.

You would vaccinate your children, correct?

Of course I would, if Im in a surrounding where there is... You know, I would not vaccinate a child in New York City for polio, because it doesnt exist. But I would for measles, because it does exist.

Even if the child was in this state that you call perfect health?

The child is in a state of perfect health if its born normally. Its in a state of homeostasis. But we also live in a world that has environmental toxins, that has climate change, that has extinction of species, that has poison in our food chain, and that is ready for extinction. And all of that is the projection of our collective insanity.

You say, The cause of disease is often extremely complex, but one thing can be said for certain: no one has proved that getting sick is necessary.

Right. My own situation says that.

Because youve never been sick.

Yes.

Because youre in this place called perfect health?

Because Im aware of being aware and I can choose the experiences I want and I focus on love, compassion, joy, equanimity, and Im beyond the fear of personal death because I dont identify with my provisional, personal, so-called identity. The question you asked me when we started, How do you define yourself?I dont.

If we were all in this place, would we need medicine?

Yes. Because of the world weve created, we would, yes.

But not because

And, besides that, the ecosystem is a predatory play of consciousness where, you know, its a recycling of experience. Birth, death, illness: they are part of our provisional identity, but I dont identify with that identity. If you do not identify with the experience, if consciousness that is aware of experience, if the awareness of experience is not the experience, then youre intrinsically free of the experience. Do you know what Im saying?

Im not sure.

O.K. If you are aware of a thought, then youre not the thought, youre the awareness of the thought.

Dr. Stacia Kenet Lansman, whos a leading vaccine skeptic, cited your work as an inspiration. Do you

I have never been against vaccination.

I know you havent.

I have never spoken against medical treatment or intervention. You should do whatever works.

But do you worry that the idea that we can achieve this place of perfect health based on our own mental state can give license to anti-scientific thinking, like we see in the anti-vaccine movement?

You asked me if I worry about that. I dont worry about anything.

Which is why you havent gotten sick.

But people can take what I say and interpret it how they want to. Theres also a difference between scientism and science. Science is a very neutral activity: theories, observation, experiments, validation or invalidation. Period. I am a big proponent of science as the greatest adventure that human consciousness has taken. With scientism, its a different thing. Its being a fundamentalist and believing that science has all the solutions for human problems, including the existential dilemmas we have about our identity, our fear of old age, infirmity, and death.

There was an interview you gave many years ago, with Tony Robbins, about AIDS. Hed put forth the idea that H.I.V. is not the source of AIDS. You said, H.I.V. may be a precipitating agent in a susceptible host.The material agent is never the cause of the disease.It may be the final factor in inducing the full-blown syndrome in somebody whos already susceptible. He then asked,Butwhat made them susceptible? You answered, Their own interpretations of the whole reality that theyre participating in. Do you still feel that way about H.I.V. and AIDS?

I still feel that pathogens are precipitating factors in susceptible hosts, and that the outcome of illness and recovery is very complex. Now, having said that, when you can find a single agent that you can either attack or get rid of, then, of course, thats the solution. You know, you and I can be exposed to a pneumococcus and one person gets pneumonia and the other doesnt. So you can see that illness is not just one mechanistic happening, an encounter with the pathogen. It has to do with everything. Are you deeply rested, are you stressed, whats your nutrition, what are your personal relationships, what is your emotional stateall of these things have an influence. Every experience we have is ultimately metabolized into a molecule in the body. If I gave you bad news right now, your blood pressure would go up. In fact, if I sent a mean tweet to Mr. Trump, his blood pressure would go up even further.

You went on to say, I have a lot of patients with so-called AIDS, this label that weve given them, that are healthier than most of the population thats living in downtown Boston. They havent had a cold in ten years. And then Robbins said, But someone has told them they have this disease. You said, Yes, somebody has told them that. And Robbins says, And they bought into it. And you said, Exactly.

Listen. You can do a five-hour interviewyou can edit it into any way you want. You can take statements out of context.

No, thats the whole context.

And then you can say, This is what you said. Right? I had that experience myself as a physician. I said to the patient, You have cancer. Immediately, he looked like he was going to have a stroke. He was going to faint. And then I realized I read the wrong chart and I said, Sorry, that was somebody else. In two seconds I could see him recover from high blood pressure, sticky platelets, a jittery heart, and so on. So, you know, there is a lot more to reality than just a simple diagnosis and the label.

But to go on to the point youre just making now, about diagnosis, when Robbins said about the diagnosis of AIDS, People are accepting this, and when they accept this, what happens to them? You replied, When they accept it, then they make it happen. It is a self-fulfilling prophecy. Is that what youre saying?

Yeah. I might have said that. And, if I did, I regret it.

What I say today is, Believe the diagnosis, but dont believe the prognosis.

Youve been criticized before for selling products that people claim can help cure cancer or other diseases via meditation.

No, Ive never claimed that. No.

Never?

If you find a reference of that, let me know.

Well, there was a video called Return to Wholeness: A Mind-Body Approach to Healing Cancer. And the release about it says, Meditation and visualization are two of the most

Right. That video was a program to help people visualize and get into a relaxed state. I believe it was promoted as that on my Web site until I became aware of it, and then it was taken off.

And then you took it down?

Yeah. It was actually an artificial-intelligence program for meditation and self-regulation. And, by the way, used at many cancer-therapy clinics across the world as an aid to relaxation. [A member of Chopras staff named Cancer Treatment Centers of America as one of the clinics that use the video, but a representative for the treatment centers was unable to verify this.]

So, when you say in your best-sellers, like Super Brain, that increased self-awareness can reduce the risks of aging and help people achieve freedom and bliss, do you feel that youre doing that at all, or not?

I am. Of course. Im seventy-three years old, and I dont think my biological age is seventy-three. In fact, I have publicly declared that I am slowing down my aging process. And I think you can go on social media and look at all the pictures over the last few years and you can see, physically, that I am not looking as old, or feeling as old, as I was twenty-five years ago. I know what Ive said is outrageous, but, if people actually listen carefully, they will see that they determine a lot of what goes into well-being and health. And, ultimately, I dont think that health is physical at all. Because, ultimately, we are all going to die, and all going to have some kind of infirmity. But most of what we do is creating anxiety from living a full life in the present moment.

So you feel that youve reached a different stage of human existence?

Im just following the example of people who have lived long, healthy lives without any infirmity and died peacefully in meditation. In the Indian tradition, its called mahasamadhithe big meditation.

When youre selling books by saying that theres a network of intelligence in the human body that has the potential to defeat cancer, heart disease, and even aging itself, is that not selling to people that cancer can be beaten by something other than medicine?

Have you read the book? Or have you read criticisms of the book?

Ive read several of the books, and some criticisms.

So then you have to make up your own mind. Im not a purveyor of false hope. In fact, I think the term false hope is an oxymoron. Either you have hope or you dont. And those that have hope do better than those who dont.

So there is no false hope?

Its up to you how you interpret this, and it doesnt actually affect me. You know, Im at a stage in my life where Ive gone beyond criticism and/or flattery. I dont need that.

Go here to see the original:
Deepak Chopra Has Never Been Sick - The New Yorker

The Patient Perspective On Patient Centricity Insights From A Veteran Of 5 Clinical Trials – Clinical Leader

By Lori Abrams

Those who know me understand the value I put on bringing the voice of the patient and caregiver into the drug development process. They also know that I believe that todays terminology phrases like patient-centricity, patient at the center, and other sexy mottos is sometimes used by organizations to show the world that the patient is at the forefront of everything they do. But are they really? Is patient feedback on a protocol enough to prove that their voices are heard? Is providing input on an informed consent what a patient really wants to do? Maybe.

How often has an organization asked the patient and caregiver how they would like to contribute to a drug development program? If they could do anything to help bring a drug to the market, what would that look like? Moreover, if a trial participant could provide ongoing feedback that improved the patient experience, what would they contribute, and how might the trial change?

Lets try it now. I am humbled to introduce readers to Amy Butler. Together, we are going to try to shed some light on the drug development process from the perspective of a brave woman who has participated in five clinical trials. First, a brief summary of Amys experience

Amy was a medical assistant for a large obstetrics and gynecology practice near her home in McHenry, IL, where she lives with her husband and two children (along with two cats, a quacker parrot, and a corgi puppy). Advocacy has always been a part of her life, as she has a brother who is developmentally disabled. But she never expected that her biggest challenge as an advocate would be to try to save her own life.

In 2014, at 44 years of age, Amy was diagnosed with stage IV colon cancer with metastasis to the liver. At the Mayo Clinic, she had a right hemicolectomy and liver resection, along with a prophylactic hysterectomy because she discovered through genetic testing that she had a CHEK2 variant. She underwent six months of Folfox chemotherapy with Avastin and was deemed cancer-free. Nine months later, a follow-up scan revealed that she had metastatic disease in both lungs. She began Folfiri with Avastin; however, after about 10 months, scans started showing progression in her lungs.

Against her Mayo Clinic oncologists advice, she began looking into clinical trials. Fortunately, her support group Colontown (see related article) provided her with science-based information about clinical trials. Her local oncologist referred her to the University of Chicago. Over the next two years, she participated in four clinical trials. Three of the trials were immunotherapy in combination with other drugs and one was an antibody trial. Due to progression, she returned to her local oncologist and revisited standard chemotherapy for a few months, with no success. Recently, Amy was approved to start her fifth clinical trial.

Amy was kind enough to answer my questions about her journey, providing an unvarnished look at clinical trials from a patients perspective and shedding light on aspects of the clinical trial process in desperate need of improvement.

Lori Abrams: You were at the Mayo Clinic and clinical trial participation was not supported. Can you describe what occurred and why?

Amy Butler: I was at Mayo Clinic for a follow-up visit and my oncologist was going over my latest CT scan results. The scans showed that my cancer was progressing while on Folfiri chemotherapy. Upon hearing this news, I told my oncologist that I thought it was time to look into clinical trials. He didnt agree with me. His recommendation was I should take a break from chemotherapy, as I was completely worn out from treatment. He felt that after a month off I would be strong enough to start treatment again in hopes of keeping my cancer at bay. Knowing that I had a mutation in the KRAS gene, I understood that I had fewer treatment options and this terrified me. I didnt want to settle; I wanted more options. After further discussion, I was told that Mayo Clinic had no clinical trials to offer me and there was no mention of any other facilities that I should consult with.

Abrams: How did it feel when you were not offered alternative options to standard care by your Mayo oncologist? What were your next steps?

Butler: It was terrible; I felt so alone. Here I was at one of the countrys premier medical facilities, and all Im offered was to continue standard of care chemotherapy, even though it clearly wasnt working anymore. My next step was to see my local oncologist and discuss my recent scans with him. This conversation was quite different from my conversation at Mayo Clinic. My local oncologist really listened to my concerns about continuing with the same chemotherapy treatments and when I asked him about clinical trials, he was on board. I walked out of that appointment with a referral to the University of Chicago. Two weeks later, I was signing a consent form for my first clinical trial.

Abrams: How and when did you find Colontown?

Butler: When I was diagnosed with stage IV colon cancer in 2014, I followed all the rules. One of those rules was to stay off the internet. In 2016, when I learned that the cancer had metastasized to my lungs, I threw that rule out the window and began looking for answers. I came across a blog called Adventures in Living Terminally Optimistic by Tom Marsilje. Tom was an oncology researcher who was also diagnosed with colon cancer at a young age. I was inspired by Toms blog; it filled me with hope again. On his blog, Tom mentioned many colon cancer support groups. I was overwhelmed with the amount of support out there. I couldnt believe that my doctors never mentioned or recommended them.

I contacted Tom and we had a great discussion about new treatments coming for colon cancer patients. He talked to me about the different support groups and recommended that I join Colontown.

Abrams: Colontown helped you understand clinical trials. What type of information did they provide? Did they provide navigation to clinical trials? How did they help you to better understand your disease?

Butler: Colontown became my lighthouse in the dark. First, let me explain how Colontown works. When you join Colontown, the administrators invite you to join private patient-lead neighborhoods. Each neighborhood is based on the stage, tumor mutations, and metastatic disease. The clinical trial neighborhoods are broken down into groups based on microsatellite instability (MSI) status as well as mutations.

Through Colontown, I was educated about what my MSI status (mine being microsatellite stable, or MSS) and my KRAS mutation meant. Not only was I able to grasp my disease, I also met wonderful people who were going through the same thing. Within the MSS clinical trial neighborhood there is a link to the Late Stage Trial Finder that was curated by Fight CRC and created by Marsilje, a scientist and Colontown member.

Abrams: You have participated in five clinical trials. Were you asked to provide feedback (good or bad) before, during, or after your participation?

Butler: The answer to this is a resounding no. The only feedback Im asked to provide is what my side effects are during treatment.

Abrams: If you could be an advisor to drug development process at a company, what would that look like?

Butler: I believe that a patient has the right to know the results of any specialized testing that was done. Ive had to have multiple lung biopsies in clinical trials, and I wasnt told why or what they were looking for. Ive had blood draws where 15 tubes of blood were taken, and I have no idea if anything interesting was found. I think patients deserve to get some results. Pharmaceutical companies should issue symptom diaries for the trials because a patient may forget how they were feeling by the time of their next appointment. A patient wants to know how their participation helped in the clinical trial.

Abrams: Were the results of the first four studies shared with you after the study closed? Did any of the sites ever reach out with results?

Butler: No; sadly, Ive never heard any results from the clinical trials Ive participated in. I feel that the facility site should get the results and share it with the patients who participated in them.

Abrams: Would you describe some of the best practices that made you feel safe, valued, and appreciated at a clinical trial site?

Butler: The facilities nurse navigators are amazing. They are your sounding board and liaison between the patient, doctors, and pharmaceutical company. The nurses who administer the treatments are some of the kindest people that I have ever met. In one of the clinical trials I participated in, I was required to stay near the facility for 10 days for daily blood draws. This meant that I couldnt go home because I lived too far away. When I went to the clinic on a Saturday for my blood draw, one of the nurses brought her puppy and they were waiting outside for me. She knew that I was homesick, and her cuddly puppy gave me the boost I needed to get through my stay.

Abrams: Conversely, would you describe experiences that made your participation difficult and or frustrating?

Butler: Overall, the waiting time is the most frustrating part of participating in a clinical trial, especially in the larger clinics. The waiting time between the signed consent and the start date, time spent sitting in waiting rooms for blood draws and CTs, and anxiously waiting for test results.

Abrams: If you could provide feedback to a sponsor (pharmaceutical company) on how to design and execute a better clinical trial for people with cancer, what would you tell them?

Butler: I would ask the pharmaceutical companies to send surveys to the treatment sites for patients to fill out periodically. This would give the patients an opportunity to give their opinions while still remaining unidentified. I would like the sponsors to make it easier for the patients to get results of the clinical trial that they participated in.

Abrams: Have you heard the phrases I mentioned above? Patient-centricity, patient at the center, etc.? What do they mean to you?

Butler: Yes, I am familiar with those terms. For me, patient-centricity means that I have some control in my clinical trial journey. Not only am I being treated, but I am being cared about. Im not just a number.

Abrams: Amy, what do you want people to know about clinical trials and/or participating in clinical trials that we have not discussed?

Butler: I think that clinical trials should be part of the discussion early on in a patients cancer journey. Too many patients are waiting until its too late to start clinical trials because they are made to feel that its taboo to bring it up to their oncologist. I want the pharmaceutical companies to never lose sight that we are people who are desperately trying to beat cancer, or at least be able to live longer with cancer. We cant afford to waste time.

Abrams: This is Amys journey, not mine. Therefore, Amy will provide the ending to this article. I hope you have been touched by Amys words, strength, and courage. Together, we can continue to improve clinical research for the patients. They are our friends, our family members, and ourselves.

Butler: Although my participation in clinical trials has not cured me, I do believe they have extended my life. I was given a 30 percent chance to live five years when I was diagnosed, and here I am almost five years later. My disease has recently taken a dark turn, as I just learned that my fifth clinical trial has failed. My tumors have grown and now I have bone involvement. My treatment options are dwindling, but I refuse to give up because when it gets down to it, I just want to live.

Postscript: On the day of discontinuation of clinical trial No. 5, Amy decided that going back to a standard course of therapy was not going to be her path. She inquired about an NIH clinical trial. The oncologist agreed that this was a good idea. Once again, Amy left a doctors office with a good idea, but without a referral or contact name or number. However, there is good news. The following week, she was screened for a trial at NIH, and eight days later, she was accepted to be a patient participant.

About The Author:

Lori Abrams is senior director of Patient Advocacy, a new division at WCG Clinical. She previously was in R&D at Bristol-Myers Squibb for 20 years, the last five as director of Diversity and Patient Engagement. This group integrated the voice of the patient and caregiver into the clinical trial process, developed relationships in the disease-based and minority-focused communities, and helped colleagues understand the challenges of those living with diseases. You can email her at labrams@wcgclinical.com.

View post:
The Patient Perspective On Patient Centricity Insights From A Veteran Of 5 Clinical Trials - Clinical Leader

Parkinsons Disease Treatment Analysis, Trends, Top Manufacturers, Share, Growth, Statistics, Opportunities & Forecast to 2025 – The Ukiah Post

Global Parkinsons Disease Treatment Market 2019-2025 Overview

The Parkinsons disease treatment market growth was driven because of increase in the geriatric population and the rise in the occurrence of the Parkinsons disease and the funding for research.

Global Parkinsons disease treatment market is anticipated to experience the substantial growth during the forecast period. Growth in the occurrence of the Parkinsons diseases is projected to supplement the growth of global Parkinsons disease treatment market in the coming future. In addition, the combined treatments supporting in the long action of constant dopaminergic stimulation medicines, neural transplantation and gene therapy is expected to fuel the Parkinsons disease treatment market growth.

Request sample copy of Parkinsons Disease Treatment Market at: https://www.adroitmarketresearch.com/contacts/request-sample/615

Parkinsons disorder is a neurological disorder affecting the movements of body. There are five stages of this disease and can hamper the individuals leg & hand movements, facial expressions getting worse with the growing age. Increase in the elderly population related to the rise in the investments in the activities of research & development, growth in the awareness for healthcare and the neurological disorders are the factors driving the global Parkinsons disease treatment market growth over the forecast period. On the other hand, due to the presence of the other treatments is hampering the Parkinsons disease treatment market growth.

Get 10% Discount: https://www.adroitmarketresearch.com/contacts/discount/615

Current developments in the Parkinsons disease treatment, for example, combined treatment to continue the effect of constant dopaminergic stimulation medicines, gene therapy, neural transplantation, neuroprotective treatment to reduce the disease prediction and support for the neurostimulation tools are estimated to provide large development in the global Parkinsons disease treatment market growth during the forecast period. Moreover, major characteristics that are fueling the requirement and demand for the global parkinsons disease treatment market are prevalence of parkinsons disease and growth in the geriatric population. Two important characteristics that are responsible to boost the Parkinsons disease treatment market development are prevalence of the neurodegenerative syndrome and rise in the elderly population. Although, increase in the medicines in the pipeline and growth in the R&D activities are anticipated to surge the Parkinsons disease treatment market size. In addition, lack of skills for the early diagnosis and large spending on treatment is projected to bolster the development of global Parkinsons disease treatment market.

Key factor driving the growth of Parkinsons disease treatment market is the growth in the acceptance of the treatment for Parkinson disease in healthcare sector. For treating and detecting the dysfunctioning of the human beings central nervous system and the neurological damage because of lack of cells and nerves are the main function of Parkinsons disease treatment market.

Global Parkinsons disease treatment market is segmented into end-use, distribution channel, drug class and region. Based on end-use, market is divided into clinics and hospitals. On the basis of distribution channel, market is divided into retail pharmacies, online pharmacies and hospital. On considering the drug class, market is divided into MAO inhibitors, Levopoda/ Carbidopa and Dopamine Receptor Agonists.

Geographically, regions involved in the development of Parkinsons disease treatment market growth are Europe, North America and Asia Pacific. Asia Pacific is anticipated to show the rapid growth because of the increase in the trend of medical tourism and medical infrastructure. North America holds the largest

Read details of the report at https://www.adroitmarketresearch.com/industry-reports/parkinsons-disease-treatment-market

Parkinsons disease treatment market share. Europe is dominating the Parkinsons disease treatment market because of the maximum market revenue in the coming years.

Key players involved in the Parkinsons disease treatment market analysis are Teva Pharmaceutical Industries, Novartis AG, Impax Laboratories and GlaxoSmithKline.

Key Segments in the Global Parkinsons Disease Treatment Market are-

By End-Use, market is segmented into:

By Distribution Channel, market is segmented into:

By Drug Class, market is segmented into:

By Regions market is segmented into:

What to expect from the Global Parkinsons Disease Treatment Market report?

Predictions of future made for this market during the forecast period.

Information on the current technologies, trends, devices, procedures, and products in the industry.

Detailed analysis of the market segmentation, depending on the types, devices, and products.

Government regulations and economic factors affecting the growth of the market.

An insight into the leading manufacturers.

Regional demographics of the market.

Who should buy this report?

Venture capitalists, Investors, financial institutions, Analysts, Government organizations, regulatory authorities, policymakers ,researchers, strategy managers, and academic institutions looking for insights into the market to determine future strategies

Else place an Inquire before Purchase Parkinsons Disease Treatment Market Size, Status and Forecast 2025: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/615

About Us:

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Information:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

Phone No.: USA: +1 972-362-8199/ +91 9665341414

Here is the original post:
Parkinsons Disease Treatment Analysis, Trends, Top Manufacturers, Share, Growth, Statistics, Opportunities & Forecast to 2025 - The Ukiah Post

Transfusion-dependent Anemia Treatment Market Gain Impetus due to the Growing Demand over 2019 2029 – Herald Space

Treating the patients with transfusion-dependent anemia is complicated. The diagnosis of transfusion-dependent anemia is often difficult as numerous disorders might lead to transfusion-dependent anemia that includes bone marrow failure syndromes, inherited hemolytic anemias or congenital dyserythropoietic anemias. Though severe anemia leads to symptoms of reduced quality of life and fatigue, transfusion-dependent anemia upsurges the risk of organ complications caused by iron overload. It may also leads to an increased risk of the leukemia transformation. While recommending the primary therapy for treatment of transfusion-dependent anemia, the four response determinants that should be considered includes: age, endogenous erythropoietin production, karyotype and RBC transfusion burden along with duration. Majority of patients develop the transfusion-dependent anemia over their course of the disease. However, adverse effect on the natural course of transfusion-dependent anemia has merely recently appreciated. As per a study conducted by World Health Organization, about 15% of the anemic cancer patients are treated via RBC transfusions. Unfortunately, treatment of chronic anemia with recurrent transfusions is done followed with associated hazards.

The increasing FDA approval for drugs that effectively treats transfusion-dependent anemia across the globe is expected to drive revenue growth in the transfusion-dependent anemia treatment over the forecast years. The higher incidence of anemia along with other infections in transfusion-dependent patients is further expected to drive the need for transfusion-dependent anemia treatment therapies. The growing commercialization of transfusion-dependent anemia treatment therapies such as allogeneic stem cell therapy would cater revenue opportunities in global transfusion-dependent anemia treatment market. However, increase in mortality rate for the patients suffering with transfusion-dependent anemia owing to high costs of the treatment therapies is anticipated to restrain the growth of transfusion-dependent anemia treatment market.

Get Sample Copy of this report at https://www.persistencemarketresearch.com/samples/3639?source=atm

The global transfusion-dependent anemia treatment market is segmented on basis of treatment type, distribution channel and geographic region:

Segmentation by Treatment Type Therapeutic Drugs Erythroid-Stimulating Agents (ESAs) Immunomodulatory Drugs Hypomethylating Drugs Others Allogeneic Stem Cell Therapy Gene Therapy

Segmentation by Distribution Channel Institutional Sales Hospitals Ambulatory Surgical Centers (ASCs) Specialty Clinics Retail Sales Hospital Pharmacies Retail Pharmacies Online Pharmacies Drug Stores

Request to view TOC at https://www.persistencemarketresearch.com/toc/3639?source=atm

The transfusion-dependent anemia treatment market is categorized based on treatment type, distribution channel and region. Based on treatment type, the transfusion-dependent anemia treatment is classified into three major treatment types including therapeutic drugs, gene therapy and allogeneic stem cell therapy. Among the transfusion-dependent anemia treatment drugs, immunomodulatory drugs are the most preferred transfusion-dependent anemia treatment drug type. This drug type segment is expected to expand at a substantial CAGR over the forecast years. Hospital pharmacies and retail pharmacies followed by hospitals is projected to register substantial revenue growth over the forecast period.

On the basis of geography, North America transfusion-dependent anemia treatment market will show highest market growth and is expected to dominate the global transfusion-dependent anemia treatment market in the forecast period owing to the growing prevalence of transfusion-dependent anemia in the region. Also, increasing health care spending coupled with availability of skilled healthcare professionals and availability of better treatments options is anticipated to boost the transfusion-dependent anemia treatment growth in this region. The transfusion-dependent anemia treatment market in South Asia and East Asia countries is expected to show a significant CAGR growth in the transfusion-dependent anemia treatment market owing larger patients pool. However, the market for transfusion-dependent anemia treatment in Latin America and the Middle East and Africa regions are estimated to register slow growth over the forecast period.

Some of the major key manufacturers involved in global Transfusion-dependent Anemia Treatment market are bluebird bio, Inc., Novartis AG, Takeda Pharmaceuticals, Acceleron Pharma, Inc., Celgene Corporation and others.

The report covers exhaustive analysis on: Transfusion-dependent Anemia Treatment Market Segments Transfusion-dependent Anemia Treatment Market Dynamics Historical Actual Market Size, 2014 2018 Transfusion-dependent Anemia Treatment Market Size & Forecast 2019 to 2029 Transfusion-dependent Anemia Treatment Market Current Trends/Issues/Challenges Competition & Companies involved Transfusion-dependent Anemia Treatment Market Drivers and Restraints

Regional analysis includes North America Latin America Europe East Asia South Asia Oceania The Middle East & Africa

Report Highlights: Shifting Industry dynamics In-depth market segmentation Historical, current and projected industry size Recent industry trends Key Competition landscape Strategies of key players and product offerings Potential and niche segments/regions exhibiting promising growth A neutral perspective towards market performance

Buy Full Report at https://www.persistencemarketresearch.com/checkout/3639?source=atm

See more here:
Transfusion-dependent Anemia Treatment Market Gain Impetus due to the Growing Demand over 2019 2029 - Herald Space